Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

A. Dodero, A. Guidetti, A. Tucci, F. Barretta, M. Novo, L. Devizzi, A. Re, A. Passi, A. Pellegrinelli, G. Pruneri, R. Miceli, A. Testi, M. Pennisi, M. C. Di Chio, P. Matteucci, C. Carniti, F. Facchetti, G. Rossi, P. Corradini

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)1047-1051
Number of pages5
Issue number4
Publication statusPublished - Apr 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this